Will Getting A Testosterone Shot Make You Lose Sleep ~ BlackHat Home Design

Will Getting A Testosterone Shot Make You Lose Sleep

The Short-Term Effects of High-Dose Testosterone on Sleep, Breathing, and Function in Older Men

Peter Y. Liu,

1Department of Andrology, ANZAC Research Institute and Concord Hospital (P.Y.L., S.M.W., M.J., D.J.H.), Sydney, 2139 Australia

Search for other works by this author on:

Brendon Yee,

2Woolcock Institute of Medical Research and Royal Prince Alfred Hospital (B.Y., D.G.J., R.R.G.), University of Sydney, Sydney, 2139 Australia

Search for other works by this author on:

Susan M. Wishart,

1Department of Andrology, ANZAC Research Institute and Concord Hospital (P.Y.L., S.M.W., M.J., D.J.H.), Sydney, 2139 Australia

Search for other works by this author on:

Mark Jimenez,

1Department of Andrology, ANZAC Research Institute and Concord Hospital (P.Y.L., S.M.W., M.J., D.J.H.), Sydney, 2139 Australia

Search for other works by this author on:

Dae Gun Jung,

2Woolcock Institute of Medical Research and Royal Prince Alfred Hospital (B.Y., D.G.J., R.R.G.), University of Sydney, Sydney, 2139 Australia

Search for other works by this author on:

Ronald R. Grunstein,

2Woolcock Institute of Medical Research and Royal Prince Alfred Hospital (B.Y., D.G.J., R.R.G.), University of Sydney, Sydney, 2139 Australia

Search for other works by this author on:

David J. Handelsman

1Department of Andrology, ANZAC Research Institute and Concord Hospital (P.Y.L., S.M.W., M.J., D.J.H.), Sydney, 2139 Australia

*Address all correspondence and requests for reprints to: Prof. David J. Handelsman, ANZAC Research Institute, Sydney NSW 2139 Australia.

Search for other works by this author on:

Received:

12 February 2003

Published:

01 August 2003

Androgen therapy may precipitate obstructive sleep apnea in men. Despite increasing androgen use in older men, few studies have examined sleep and breathing. Randomized, double-blind, placebo-controlled studies examining effects of testosterone simultaneously on sleep, breathing, and function in older men are not available. Seventeen community-dwelling healthy men over the age of 60 yr were randomized to receive three injections of im testosterone esters at weekly intervals (500 mg, 250 mg, and 250 mg) or matching oil-based placebo and then crossed over to the other treatment after 8 wk of washout. Polysomnography, anthropometry, and physical, mental, and metabolic function were assessed at baseline and after each treatment period. Testosterone treatment reduced total time slept (∼1 h), increased the duration of hypoxemia (∼5 min/night), and disrupted breathing during sleep (total and non-rapid eye movement respiratory disturbance indices both increased by approximately seven events per hour) (all P < 0.05). Despite expected effects on body composition (increase in total and lean mass, reduction in fat mass, P < 0.05, bioimpedance method), upper airway dimensions did not change (acoustic reflectometry). Driving ability (computer simulation), physical activity (accelerometry, Physical Activity Scale in the Elderly), quality of life (SF36, Functional Outcomes of Sleep Questionnaire), mood (Profile of Mood States Questionnaire), sleepiness (Epworth, Stanford scales), and insulin resistance (homeostasis model) also were not changed by treatment. Short-term administration of high-dose testosterone shortens sleep and worsens sleep apnea in older men but did not alter physical, mental, or metabolic function. These changes did not appear to be due to upper airway narrowing. Further study of longer-term lower-dose androgen therapy on sleep and breathing is needed to evaluate its safety in older men.

OBSTRUCTIVE SLEEP APNEA (OSA) can cause death as well as cardiovascular, metabolic, and neuropsychological morbidity. Its prevalence increases with age, has a male preponderance with up to 25% of working age men having disturbed breathing during sleep (1), and up to 80% of cases of OSA remain undiagnosed. The pathophysiological basis of OSA is periodic airway occlusion resulting in sleep and blood gas disturbance that leads to cardiovascular disease, hypertension, arrhythmia, increased risk of traffic accidents, disturbed psychosocial performance, and metabolic and neuroendocrine dysfunction (2).

Androgen treatment has long been believed to precipitate OSA in some men (3). However, few studies have systematically examined the effect of androgen treatment on breathing or sleep (4–9). There are no randomized placebo-controlled studies that have examined the effect of androgen treatment on both sleep and breathing, although one has reported no reduction in sleep (7) and the other no worsening of breathing (9). Furthermore, no study has shown that androgen treatment shortens sleep or impairs physical or mental function. Although inconsistent effects on sleep architecture are reported, the paucity of well-designed studies using gold standard endpoints (such as overnight polysomnography) means that the safety of androgen therapy during sleep remains uncertain.

Concurrently there is increased interest in the use of androgen supplementation in older men to improve body composition, muscle and bone strength, and physical functioning (10–19). These studies have consistently recruited men over 60 yr of age with baseline plasma testosterone concentrations ≤430 ng/dl (15 nmol/liter, which includes the lower end of the young eugonadal male reference range) because men with lower baseline testosterone concentrations are more likely to be androgen responsive (14, 20). Most of these studies have treated men for less than 6 months, and there are no long-term studies of high-dose testosterone treatment. Because of the paucity of data, this study was designed to examine the safety of short-term, high-dose testosterone treatment on sleep, breathing, and mental and physical function in older men, and, therefore, the duration of exposure was minimized to reduce the risk to participants.

Subjects and Methods

Study design

The study was designed as a randomized sequence, double blind, placebo-controlled cross-over study of 17 eligible and evaluable men (Fig. 1). Subjects were randomly assigned to receive either testosterone esters (250 mg/ml, Sustanon 250, Organon Australia, Sydney, Australia) or arachis oil volume-matched placebo (Department of Pharmacy, Concord Hospital) during the first period before crossing over to the other treatment. Each treatment period consisted of three im injections spaced 1 wk apart. The first injection was 2 ml (equal to 500 mg testosterone esters in the treatment group), and the subsequent two injections were 1 ml (250 mg testosterone ester) each. There was a washout period of 8 wk between the two treatment periods, which would allow complete clearance of administered testosterone. All injections were administered by staff of the Department of Andrology. Subjects were advised to report any injection-related (stinging, bruising, or pain) adverse event. Adverse events or intercurrent illness and their likely relationship with drug administration were recorded prospectively. Anthropometry, sleep studies, driving, and physical and mental function were assessed at baseline and after each study period (2–4 d after the last im injection to capture the maximal circulating testosterone concentrations). More easily obtained variables [blood, SF36, International Prostate Symptom Score (IPSS), Physical Activity Scale in the Elderly (PASE) ] in subjects were obtained at 1- to 2-wk intervals (Fig. 1). All study procedures were approved by the CSAHS Ethics Committee within National Health and Medical Research Council (Australia) guidelines. The trial was conducted under the TGA (Australia) clinical trial notification scheme.

Fig. 1.

Study design. For further details see text.

Fig. 1.

Study design. For further details see text.

Subjects and treatment

Healthy, ambulatory and community-dwelling men older than 60 yr of age were recruited if they had a plasma testosterone ≤430 ng/dl (15 nmol/liter) on two separate occasions. They were excluded because of: 1) presence of severe snoring or sleepiness requiring investigation and treatment; 2) contraindication to testosterone use including breast cancer, prostate cancer, or disease requiring further treatment; 3) unstable, uncontrolled or severe chronic medical disease; 4) medical conditions that might interfere with evaluation of sleep or physical activity (including physical incapacity or dementia); or 5) medication use known to interact with sex steroid action or alter sleep

Study procedures

Volunteers were recruited through public advertisement. Respondents were provided with an explanation of the study and a written information sheet and were required to sign a consent form. Standardized medical history, physical examination, and blood samples were obtained at entry. Fasting blood samples were taken between 0830 and 1030 h before injection of study drug, and participants were asked not to vary their diet or exercise patterns. Eligible subjects who satisfied all entry criteria were randomly assigned a study number that corresponded with individually numbered drug supplies. The Department of Pharmacy (Concord Hospital) held the randomization list (obtained by random-number generator) and dispensed all study medications. At the end of the study, subjects nominated the period during which active treatment was administered to assess adequacy of blinding.

Assays and insulin sensitivity

Serum samples were stored frozen for measurement, within a single assay, using commercially available DELFIA immunoassays (Perkin-Elmer Life Sciences, Rowville, Australia) for LH, FSH, total testosterone, SHBG, insulin, and prostate-specific antigen (PSA). Leptin was measured by double-antibody RIA (Linco Research Inc., St Louis, Mo) assay. Blood glucose was determined by the hexokinase method (Hitachi 917 autoanalyzer, Roche Diagnostics, Castle Hill, Australia) from blood collected in sodium fluoride (Vacutainer; Becton Dickinson, Rutherford, NJ) during the previous 2 h. Within assay coefficients of variation were less than 10% for all assays, and detection limits for gonadotropin assays were 0.1–0.2 IU/liter. Insulin resistance and production were calculated according to the homeostasis model (21).

Anthropometry and upper airway caliber

Anthropometry and upper airway caliber were assessed in all subjects on three occasions (baseline, end of phase 1, and end of phase 2) by a single observer. Anthropometric (22) and bioimpedance measurements were taken while fasting before the first and last injection of each study phase immediately after micturition as previously reported (19). Lean mass was estimated from bioimpedance (SEAC model BIM 3.0 bioimpedance meter, Inderlec, Brisbane, Australia) according to Lukaski and Bolunchuk's formula and fat mass, obtained by subtraction from body weight (23).

Upper airway caliber was assessed by acoustic reflectometry (24) (Eccovision pharyngometer; E. Benson Hood Laboratories, Pembroke, MA). Airway dimension at the pharynx, glottis, and oropharyngeal junction were measured with the subject awake and in four positions (supine, erect, and in the left and right lateral) while breathing quietly at tidal volume.

Polysomnography

Sleep and breathing were assessed by full overnight polysomnography (at RPAH Sleep Disorders Centre) after one night of laboratory acclimatization in all subjects on three occasions (baseline, end of phase 1, and end of phase 2) and as previously described (25). Chest wall and abdominal motion were recorded using Respitrace (Ambulatory Monitoring Inc., Ardsley, NY), airflow was measured by nasal pressure (pressure transducer; Validyne, Northridge, CA) and arterial oxyhemoglobin saturation with a Biox 3700e (Ohmeda, Louisville, CO). Subjects were asked to maintain their usual sleeping pattern (and not to nap during the day) before sleep studies. Data were recorded continuously on a computerized polygraph (Compumedics E series, Melbourne, Australia) and scored by a single blinded technologist using American Academy of Sleep Medicine consensus methods (26) to calculate respiratory disturbance indices and sleep stage. In brief, apneas occurred when airflow ceased, whereas hypopneas occurred when airflow or thoracoabdominal movement fell by at least 50%. Apneas and hypopneas had to be of at least 10 sec duration and were classified as obstructive if there was continued diaphragm electromyographic activity or thoracoabdominal wall movement otherwise they were central. The total respiratory disturbance index (RDI) was calculated as the number of apneas and hypopneas that occurred per hour of sleep and were subdivided into rapid eye movement (REM) RDI and non-REM (NREM) RDI according to whether events occurred in REM or NREM sleep, respectively. Sleep stages [sleep stage 1 (S1), 2 (S2), 3 (S3), 4 (S4), NREM, and REM sleep] were defined by standard electroencephalographic criteria (26). Sleep efficiency (the proportion of time slept while in bed), sleep-related hypoxemia (oxygen saturation <90%, during sleep), and nadir oxygen saturation during sleep were also determined.

Driving performance task

Driving ability was assessed by computer simulation (27) in a darkened room (AusEd, Diagnose IT, Sydney, Australia) at baseline and after each study phase. In brief, all subjects performed a 30-min driving performance task after a 20-min practice session in a darkened room at 2000 h in the evening. The object of the test was to steer an image of a car hood along a predefined monotonous, night-driving course as accurately as possible within a velocity range indicated on a screen speedometer. To test vigilance and reaction time, subjects had to brake when a visual image of a truck randomly appeared. The driving simulator recorded tracking error (ability to steer accurately), velocity deviation (time outside mandatory speed range), reaction time (average time to respond to visual stimulus), and number of crashes.

Physical activity and questionnaires

Physical activity was determined objectively by accelerometry (TriTrac R3D ergometer; ZMD Reining Inc., Madison, WI) (28) using the manufacturer's proprietary software (Tritrac R3D software, version 6.05) and by PASE questionnaire (29).

General [SF36 (30)] and sleep-specific [Functional Outcomes of Sleep Questionnaire (FOSQ) (31)[ quality of life as well as sleepiness [Stanford and Epworth sleepiness scale (32)] were assessed before and after treatment in each phase of the study. Mood was assessed by the Profile of Mood States Questionnaire (POMS) (33) and lower urinary tract symptoms associated with prostate growth were assessed by the IPSS (34).

Statistical analysis

The randomization code was not broken until all data were collected and the resulting database cleaned and locked. Standard techniques to transform nonnormal data (Shaprio-Wilk test) and examine for carryover and period effects were used (35). Response to testosterone treatment was analyzed by paired t test (35). For data with repeated measures, treatment and placebo data were pooled separately by averaging and then analyzed analogously. These results were confirmed by a two-way ANOVA model with main effects for order (placebo or testosterone treatment first) and time, with repeated measures on time. In this model, treatment effect was determined by the interaction between order and time and period effects by the time variable. The results of this method are not presented unless they differ significantly from the previous. Pearson's correlations were determined to assess linear associations between baseline hormonal data and change in breathing or sleep. All data are expressed as mean ± sem. Data were considered significantly different at P ≤ 0.05 (two sided). Analyses were performed using SPSS 10.0 (SPSS Inc., Chicago, IL).

Results

Characteristics and disposition of participants

Seventeen eligible men aged 67.5 ± 0.8 (sem) yr were recruited with nine receiving testosterone first. One subject was discontinued at the end of the second period (while on placebo) because of recurrence of long-standing cervical neck pain. There were no other serious adverse events, and no adverse event was considered to be drug related except for two men who had transient nipple tenderness while receiving testosterone and injection-related pain that occurred in three of 102 injections.

Sixteen evaluable men completed the study. There were no missing appointments and minimal missing data (<1%) arising from equipment failure. Period and carryover effects were not detected. Subjects were unable to correctly predict their treatment assignments at the end of the study (only 65% guessed correctly, P = 0.33) suggesting adequate blinding.

Hormonal and anthropometric effects

Testosterone treatment significantly suppressed LH and FSH to the detection limit of the assay and markedly increased serum total testosterone and estradiol by 2- to 3-fold (Fig. 2). Leptin fell, but there were no significant changes in SHBG, insulin, glucose, or PSA (not all data shown). IPSS (lower urinary tract symptoms) was not changed by treatment (not shown).

Fig. 2.

Plot of mean and se of mean for blood parameters. The left plot (light gray) shows baseline, and the right plot shows the change from baseline in the pooled testosterone (dark gray) and pooled placebo (white) groups. Significant differences among groups are indicated by the asterisk. Note significant change in leptin, FSH, LH, estradiol (E2), and testosterone (T). In some instances the scale of the left and right plots differ. To convert values for estradiol from pmol/liter (pm) to pg/ml, divide by 3.671. To convert values for testosterone from nmol/liter (nm) to ng/dl, divide by 0.03467. For further details, see text.

Fig. 2.

During treatment, testosterone significantly increased total weight (∼2 kg) and lean mass (∼3 kg) and reduced fat mass (∼1 kg) (Fig. 3). There was no significant change in either abdominal or neck circumferences or in upper airway caliber (data not shown).

Fig. 3.

Plot of mean and se of mean for anthropometric parameters. The left plot (light gray) shows baseline, and the right plot shows the change from baseline in the pooled testosterone (dark gray) and pooled placebo (white) groups. Significant differences between groups are indicated by the asterisk. Note significant change in total, lean and fat mass, and BMI. In some instances the scale of the left and right plots differ. For further details, see text.

Fig. 3.

Polysomnography

Total time slept was shorter on testosterone treatment (∼1 h) with a reduction in both NREM (particularly stage 2) and REM sleep as well as sleep efficiency (Fig. 4). The proportion of total time slept in NREM and REM sleep did not change (data not shown). The total RDI (∼7 events/h) was increased by testosterone, and this was due predominantly to events occurring in NREM sleep (∼7 events/h, Fig. 5). Absolute (∼5 min) and relative (as a proportion of total time slept, by ∼2%) hypoxemia was prolonged, but nadir oxygen saturation was not altered by testosterone treatment (Fig. 5).

Fig. 4.

Plot of mean and se of mean for polysomnographic sleep parameters. The left plot (light gray) shows baseline, and the right plot shows the change from baseline in the pooled testosterone (dark gray) and pooled placebo (white) groups. Significant differences among groups are indicated by the asterisk. Note significant decrease in total, REM, and non-REM time slept. Time in stage 2 sleep is also significantly reduced. In some instances the scale of the left and right plots differ. Sleep stages are abbreviated as sleep stage 1 (S1), 2 (S2), 3 (S3), 4 (S4), REM, and NREM sleep. For further details, see text.

Fig. 4.

Fig. 5.

Plot of mean and se of mean for polysomnographic breathing parameters. The left plot (light gray) shows baseline, and the right plot shows the change from baseline in the pooled testosterone (dark gray) and pooled placebo (white) groups. Significant differences among groups are indicated by the asterisk. Note significant change in total and NREM RDI, sleep efficiency, and absolute and relative duration of hypoxemia. In some instances the scale of the left and right plots differ. For further details, see text.

Fig. 5.

To determine whether any baseline hormonal or sleep variables were predictive of worse sleep response to testosterone treatment, Pearson's correlations were determined. No significant associations were found (data not shown). In particular, baseline total testosterone was not significantly correlated with change in total RDI, NREM RDI or REM RDI, or time slept in total or during NREM or REM sleep (all P > 0.05). Furthermore, baseline total RDI was not significantly correlated with change in total RDI, NREM RDI or REM RDI, or time slept in total or during NREM or REM sleep (all P > 0.05).

Physical and mental function and quality of life

Driving ability (ability to steer and maintain constant speed, crashes, and divided attention) was not altered by testosterone treatment. Physical activity (accelerometry and PASE), mood (POMS), sleepiness (Epworth and Stanford), and quality of life (FOSQ and SF-36) were not altered by testosterone treatment. Metabolic function (homeostasis model assessment-derived insulin resistance and production) was unchanged. (Fig. 6, not all data shown).

Fig. 6.

Plot of mean and se of mean for physical and mental function and quality of life. The left plot (light gray) shows baseline, and the right plot shows the change from baseline in the pooled testosterone (dark gray) and pooled placebo (white) groups. Significant differences among groups are indicated by the asterisk. No significant changes were detected in homeostasis model assessment (HOMA) determined insulin resistance or insulin production, FOSQ, total SF36 score, Epworth or Stanford sleepiness scales, PASE, the vigor component of the POMS, or steering or speed deviation of the driving performance task. In some instances the scale of the left and right plots differ. For further details, see text.

Fig. 6.

Discussion

This is the first randomized placebo-controlled study to show that high-dose testosterone therapy can disrupt sleep and breathing, increase sleep-related hypoxemia, and potentially precipitate obstructive sleep apnea. It resolves the uncertainty arising from the original case report (3, 36) and subsequent contradictory and inconclusive randomized studies (6, 9). Furthermore, this is the first study to show that high-dose testosterone therapy can shorten time slept, although inconsistent effects on sleep architecture have been previously described (7). Sleep loss of the magnitude described in this study can impair cognitive and physical performance in younger individuals (37), and the combination of reduction in sleep time and obstructive sleep apnea is particularly harmful because sleep deprivation can worsen disordered breathing (38). In addition, the absolute and relative (to the proportion of total time slept) duration of hypoxemia increased, although there was no reduction in nadir oxygen saturation. This study, therefore, underlines the safety concerns of testosterone treatment in older men.

Despite worsened breathing, lengthened hypoxemia, and shortened sleep, no alteration in physical or mental function (driving ability, self-reported and objectively recorded physical activity, mood, sleepiness, or quality of life) or metabolic function (insulin resistance) was detected, although changes may have occurred with prolonged therapy. Insulin resistance is associated with OSA (39–41) independent of visceral obesity (42, 43), and it may be that there was no net effect because disordered breathing worsens and reduced adiposity improves insulin action. It is possible that the short duration of high-dose androgen therapy chosen (to minimize any potential adverse effects) was not long enough to cause detectable physical, mental or metabolic changes, particularly because the increase in sleep-disordered breathing and duration of hypoxemia were both moderate in magnitude. However, prolonged therapy, which would be required to maintain body compositional and other physical performance improvements in older men, may have resulted in chronic low-level hypoxemia leading to impaired cardiovascular, neurological, and physical function. In addition, sleep deprivation, particularly when sustained, will impair physical and mental function in older individuals, although the magnitude of the effect is reduced, compared with the young (44).

Alternatively, napping during the day (against specific instructions) may have compensated for the decrease in sleep at night, but there is no evidence for this. It is also possible that the methods used were not sensitive enough to detect subtle changes in physical, mental, or metabolic function. However, our methods to measure driving ability, physical activity, and insulin resistance are validated (21, 27–29, 45) and widely used.

Testosterone may worsen breathing by a number of mechanisms because upper airway patency is determined by many structural and neuromuscular factors that control pharyngeal airway size and collapsibility. Obesity, as reflected by body mass index (BMI) and neck circumference (46), is associated with OSA. However, this association is explained by upper airway narrowing (24) probably via pharyngeal fat deposition (47, 48). Although testosterone treatment resulted in an increase in BMI, adiposity (and presumably pharyngeal fat) was reduced (as measured by bioimpedance), consistent with the observed reduction in serum leptin concentration. It is also possible that these rapid change in body composition reflect changes in hydration because of high doses of testosterone used in a short period of time and that the disturbed breathing arose from upper airway edema. However, fluid shifts do not occur in young men treated with comparable doses of testosterone esters (49). Furthermore, direct measurement of upper airway caliber (by acoustic reflectometry) at the narrowest (the oropharyngeal junction) and widest (maximal pharyngeal area) locations, as well as neck or abdominal circumferences, did not change with treatment. Because these measurements were performed with the subjects awake, we cannot exclude the possibility that upper airway narrowing may have occurred specifically during sleep. Although a direct anabolic effect on upper airway soft tissue growth could result in a physical reduction in upper airway dimension and this is thought to be how androgens induce OSA in women (50–52), the duration of therapy in this study was too short for this to have occurred.

Testosterone may worsen breathing by neuromuscular mechanisms. Testosterone treatment increases upper airway collapsibility (53), ventilation (54), and hypoxic (54) and hypercapnic ventilatory responses (55), leading to a reduced apneic threshold. These effects on breathing may occur particularly during NREM sleep (55), which is consistent with our findings.

Although androgen deficiency, particularly in older men, is associated with insomnia and other sleep disturbances, a marked reduction in time slept with testosterone administration was actually observed. It may be that high and low circulating testosterone concentrations are both associated with sleep disturbances. Testosterone may directly alter sleep through central nervous system effects including altered serotingergic neurotransmission (56). Testosterone increases nocturnal metabolic rate (54), potentially impairing sleep quality (57).

An important caveat of this study was that, as expected, treatment resulted in high supraphysiological serum testosterone concentrations and sleep and function were measured at the time of expected peak concentrations. Such high doses have been used therapeutically in pilot studies in older men (58), but there are no long-term studies and on the basis of our findings, long-term, high-dose androgen use in older men cannot be recommended, although the safety of long-term, low-dose androgen use remains to be clarified. Hence, our findings are applicable mostly to short-term, high-dose testosterone ester administration and may not be applicable to lower-dose physiological replacement, particularly with preparations (such as transdermal or subdermal testosterone therapy), which do not result in supraphysiological peak serum concentrations (9). Nevertheless, im testosterone ester administration is a widely used and studied form of therapy among older men (10–13, 17).

We also observed the phenomenon of "regression to the mean" (59) in baseline testosterone concentrations, whereby despite screening requirements of less than 430 ng/dl (15 nmol/liter), the subsequent pretreatment baseline testosterone concentration was modestly higher (16, 19). Hence, many of our men had a baseline testosterone within the young normal range. We also showed that a lower baseline testosterone or a higher baseline total respiratory disturbance index was not linearly associated with greater worsening of any breathing or sleep parameter. This suggests that excluding subjects for androgen therapy on the basis of preexisting OSA may not be sufficient, and conversely, hypogonadal men with coexistent OSA should not necessarily be denied androgen therapy. Nevertheless, monitoring of sleep and breathing would be prudent in hypogonadal men with symptoms (e.g. snoring, daytime sleepiness, morning headache) of or risk factors (e.g. obesity) for OSA commencing androgen replacement, particularly replacement with im testosterone esters (3, 4–7, 53). This is particularly prudent because this study specifically included men without symptoms of severe OSA and may, therefore, have excluded men who may have been more adversely affected by androgen therapy. However, at baseline many of the men had disturbed breathing, defined polysomnographically, consistent with men of this age. The clinical significance of these laboratory-based measurements is uncertain in the absence of symptoms of OSA. However, no man was diagnosed with severe OSA requiring treatment, although four men were offered further evaluation and two men subsequently received a trial of continuous positive airway pressure.

Short-term prostate safety was suggested by the lack of change in PSA and IPSS, consistent with other longer-term but lower-dose studies (14, 16, 19). Uniquely, this study shows that high-dose treatment, sufficient to increase serum testosterone and estradiol by 2- to 3-fold will not acutely alter PSA or induce lower urinary tract symptoms in older men if ultrashort duration therapy is used.

Nevertheless, this study raises concerns about the safety of long-term androgen therapy in older men with partial age-related androgen deficiency. Consideration for breathing and sleep safety must now be placed alongside concerns regarding prostate disease (60) and polycythemia (61). Given the recently recognized adverse effects of hormone replacement therapy in older women (62), this is a salutatory reminder that high-quality studies examining both efficacy and safety are required before widespread adoption of androgen replacement in older men can be recommended.

Acknowledgements

We are indebted to the staff of the Departments of Andrology and Pharmacy (Concord Hospital) and Centre for Respiratory Failure and Sleep Disorders (Royal Prince Alfred Hospital) for their valued help. Organon Australia donated testosterone ampoules.

This work was supported by National Health and Medical Research Council of Australia Grants 142613 and 262025. There are no financial disclosures by any of the authors. This study was presented in part during the Clinical Trials Symposium of the 84th Annual Meeting of The Endocrine Society, San Francisco, California, June 20–23, 2002.

Abbreviations:

BMI,
FOSQ,

Functional Outcomes of Sleep Questionnaire;
IPSS,

International Prostate Symptom Score;
NREM,
OSA,
PASE,

Physical Activity Scale in the Elderly;
POMS,

Profile of Mood States Questionnaire;
PSA,

prostate-specific antigen;
RDI,

respiratory disturbance index;
REM,

Young

Palta

Dempsey

Skatrud

Weber

Badr

1993

The occurrence of sleep-disordered breathing among middle-aged adults.

N Engl J Med

328

1230

–

1235

Grunstein

Hedner

Grote

2001

Treatment options for sleep apnoea.

Drugs

237

–

2351

Sandblom

Matsumoto

Scoene

Lee

Giblin

Bremner

Pierson

1983

Obstructive sleep apnea induced by testosterone administration.

N Engl J Med

308

508

–

510

Millman

Kimmel

Shore

Wasserstein

1985

Sleep apnea in hemodialysis patients: the lack of testosterone effect on its pathogenesis.

Nephron

407

–

410

Matsumoto

Sandblom

Schoene

Lee

Giblin

Pierson

Bremner

1985

Testosterone replacement in hypogonadal men: effects on obstructive sleep apnea, respiratory drives and sleep

Clin Endocrinol

713

–

721

Schneider

Pickett

Zwillich

Weil

McDermott

Santen

Varano

White

1986

Influence of testosterone on breathing during sleep.

J Appl Physiol

618

–

623

Leibenluft

Schmidt

Turner

Danaceau

Ashman

Wehr

Rubinow

1997

Effects of leuprolide-induced hypogonadism and testosterone replacement on sleep, melatonin, and prolactin secretion in men.

J Clin Endocrinol Metab

3203

–

3207

Luboshitzky

Lavi

Lavie

1999

The association between melatonin and sleep stages in normal adults and hypogonadal men.

Sleep

867

–

874

Snyder

Peachey

Hannoush

Berlin

Loh

Holmes

Dlewati

Staley

Santanna

Kapoor

Attie

Haddad

Strom

1999

Effect of testosterone treatment on bone mineral density in men over 65 years of age.

J Clin Endocrinal Metab

1966

–

1972

Tenover

1992

Effects of testosterone supplementation in the aging male.

J Clin Endocrinal Metab

1092

–

1098

Morley

Perry

Kaiser

Kraengle

Jensen

Houston

Mattammal

Perry

1993

Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study.

J Am Geriatr Soc

149

–

152

Sih

Morley

Kaiser

Perry

Patrick

Ross

1997

Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial.

J Clin Endocrinal Metab

1661

–

1667

Clague

FCW

Horan

1999

Difficulties in measuring the effect of testosterone replacement therapy on muscle function in older men.

Int Androl

261

–

265

Snyder

Peachey

Hannoush

Berlin

Loh

Lenrow

Holmes

Dlewati

Santanna

Rosen

Strom

1999

Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age.

J Clin Endocrinal Metab

2647

–

2653

Kenny

Prestwood

Gruman

Marcello

Raisz

2001

Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels

J Gerontol Ser A Biol Sci Med Sci

M266

–

M272

Jimenez

Zhuang

Celermajer

Conway

Handelsman

2001

A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency.

J Clin Endocrinol Metab

4078

–

4088

Ferrando

Sheffield-Moore

Yeckel

Gilkison

Jiang

Achacosa

Lieberman

Tipton

Wolfe

Urban

2002

Testosterone administration to older men improves muscle function: molecular and physiological mechanisms

Am J Physiol Endocrinol Metab

282

E601

–

E607

Lambert

Sullivan

Freeling

Lindquist

Evans

2002

Effects of testosterone replacement and/or resistance exercise on the composition of megestrol acetate stimulated weight gain in elderly men: a randomized controlled trial.

J Clin Endocrinol Metab

2100

–

2106

Liu

Wishart

Handelsman

2002

A double-blind, placebo- controlled, randomized clinical trial of recombinant human chorionic gonadotropin on muscle strength and physical function and activity in older men with partial age-related androgen deficiency.

J Clin Endocrinol Metab

3125

–

3135

Marin

Holmang

Jonsson

Sjostrom

Kvist

Holm

Lindstedt

Bjorntorp

1992

The effects of testosterone treatment on body composition and metabolism in middle-aged obese men.

Int J Obes Relat Metab Disord

991

–

997

Matthews

Hosker

Rudenski

Naylor

Treacher

Turner

1985

Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Diabetologia

412

–

419

Lohman

Roche

Martorell

1988

Anthropometric standardization reference manual

Champaign, IL

Human Kinetics Books

Lukaski

Bolonchuk

1987

Theory and validation of the tetrapolar bioelectrical impedance method to assess human body composition

In: Ellis KJ, Yasumura S, Morgan WD, eds. Proceedings of the International Symposium on In Vivo Body Composition Studies. London: Institute of Medical Physics;

410

–

414

Bradley

Brown

Grossman

Zamel

Martinez

Phillipson

Hoffstein

1986

Pharyngeal size in snorers, nonsnorers, and patients with obstructive sleep apnea.

N Engl J Med

315

1327

–

1331

Stewart

Grunstein

Berthon-Jones

Handelsman

Sullivan

1992

Androgen blockade does not affect sleep-disordered breathing or chemosensitivity in men with obstructive sleep apnea.

Am Rev Respir Dis

146

1389

–

1393

Anonymous

1999

Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force.

Sleep

667

–

689

Land

Horwood

1995

Which parts of the road guide steering?

Nature

377

339

–

340

Nichols

Morgan

Sarkin

Sallis

Calfas

1999

Validity, reliability, and calibration of the Tritrac accelerometer as a measure of physical activity.

Med Sci Sports Exerc

908

–

912

Schuit

Schouten

Westerterp

Saris

1997

Validity of the Physical Activity Scale for the Elderly (PASE): according to energy expenditure assessed by the doubly labeled water method.

J Clin Epidemiol

541

–

546

McCallum

1995

The SF-36 in an Australian sample: validating a new, generic health status measure.

Aust J Public Health

160

–

166

Weaver

Laizner

Evans

Maislin

Chugh

Lyon

Smith

Schwartz

Redline

Pack

Dinges

1997

An instrument to measure functional status outcomes for disorders of excessive sleepiness.

Sleep

835

–

843

Johns

1991

A new method for measuring daytime sleepiness: the Epworth sleepiness scale.

Sleep

540

–

545

McNair

Lorr

Droppleman

1971

EITS manual for the profile of mood states

San Diego

Educational and Industrial Testing Service

Barry

Fowler Jr

O'Leary

Bruskewitz

Holtgrewe

Mebust

Cockett

1992

The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.

J Urol

148

1549

–

1557

Pocock

1983

Clinical trials: a practical approach

Chichester (West Sussex), New

York

Wiley

Camargo

1983

Obstructive sleep apnea and testosterone (letter).

N Engl J Med

309

314

–

315

Bonnet

Arand

1995

We are chronically sleep deprived.

Sleep

908

–

911

Persson

Svanborg

1996

Sleep deprivation worsens obstructive sleep apnea. Comparison between diurnal and nocturnal polysomnography.

Chest

109

645

–

650

Grunstein

Stenlof

Hedner

Sjostrom

1995

Impact of obstructive sleep apnea and sleepiness on metabolic and cardiovascular risk factors in the Swedish Obese Subjects (SOS) Study.

Int J Obes Relat Metab Disord

410

–

418

Vgontzas

Papanicolaou

Bixler

Hopper

Lotsikas

Lin

Kales

Chrousos

2000

Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia.

J Clin Endocrinol Metab

1151

–

1158

Brooks

Cistulli

Borkman

Ross

McGhee

Grunstein

Sullivan

Yue

1994

Obstructive sleep apnea in obese noninsulin-dependent diabetic patients: effect of continuous positive airway pressure treatment on insulin responsiveness.

J Clin Endocrinol Metab

1681

–

1685

Lam

Tsang

Lam

2002

Obstructive sleep apnea is independently associated with insulin resistance.

Am J Respir Crit Care Med

165

670

–

676

Punjabi

Sorkin

Katzel

Goldberg

Schwartz

Smith

2002

Sleep-disordered breathing and insulin resistance in middle-aged and overweight men.

Am J Respir Crit Care Med

165

677

–

682

Smulders

Kenemans

Jonkman

Kok

1997

The effects of sleep loss on task performance and the electroencephalogram in young and elderly subjects.

Biol Psychol

217

–

239

Turkington

Sircar

Allgar

Elliott

2001

Relationship between obstructive sleep apnoea, driving simulator performance, and risk of road traffic accidents.

Thorax

800

–

805

Katz

Stradling

Slutsky

Zamel

Hoffstein

1990

Do patients with obstructive sleep apnea have thick necks?

Am Rev Respir Dis

141

1228

–

1231

Shelton

Woodson

Gay

Suratt

1993

Pharyngeal fat in obstructive sleep apnea.

Am Rev Respir Dis

148

462

–

466

Schwab

Gupta

Gefter

Metzger

Hoffman

Pack

1995

Upper airway and soft tissue anatomy in normal subjects and patients with sleep-disordered breathing. Significance of the lateral pharyngeal walls.

Am J Respir Crit Care Med

152

1673

–

1689

Bhasin

Woodhouse

Casaburi

Singh

Bhasin

Berman

Chen

Yarasheski

Magliano

Dzekov

Bross

Phillips

Sinha-Hikim

Shen

Storer

2001

Testosterone dose-response relationships in healthy young men

Am J Physiol Endocrinol Metab

281

E1172

–

E1181

Fogel

Malhotra

Pillar

Pittman

Dunaif

White

2001

Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome.

J Clin Endocrinol Metab

1175

–

1180

Dexter

Dovre

1998

Obstructive sleep apnea due to endogenous testosterone production in a woman.

Mayo Clin Proc

246

–

248

Johnson

Anch

Remmers

1984

Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration.

Am Rev Respir Dis

129

1023

–

1025

Cistulli

Grunstein

Sullivan

1994

Effect of testosterone administration on upper airway collapsibility during sleep.

Am J Respir Crit Care Med

149

530

–

532

White

Schneider

Santen

McDermott

Pickett

Zwillich

Weil

1985

Influence of testosterone on ventilation and chemosensitivity in male subjects.

J Appl Physiol

1452

–

1457

Zhou

Rowley

Demirovic

Diamond

Badr

2003

Effect of testosterone on the apneic threshold in females during NREM sleep.

J Appl Physiol

101

–

107

Fink

Sumner

Rosie

Wilson

McQueen

1999

Androgen actions on central serotonin neurotransmission: relevance for mood, mental state and memory.

Behav Brain Res

105

–

Bonnet

Arand

1995

24-Hour metabolic rate in insomniacs and matched normal sleepers.

Sleep

581

–

588

Amory

Chansky

Camuso

Hoey

Anawalt

Matsumoto

Bremner

2002

Preoperative supraphysiological testosterone in older men undergoing knee replacement surgery.

J Am Geriatr Soc

1698

–

1701

Bland

Altman

1994

Regression towards the mean.

BMJ

308

1499

Handelsman

1998

The safety of androgens: prostate and cardiovascular disease. In: Wang C, ed

Male reproductive function. Boston

Kluwer Academic Publishers; 227–237.

Drinka

Jochen

Cuisinier

Bloom

Rudman

1995

Polycythemia as a complication of testosterone replacement therapy in nursing home men with low testosterone levels.

J Am Geriatr Soc

899

–

901

Rossouw

Anderson

Prentice

LaCroix

Kooperberg

Stefanick

Jackson

Beresford

Howard

Johnson

Kotchen

Ockene

2002

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.

JAMA

288

321

–

333

55,500 Views

156 Citations

Email alerts

Citing articles via

Will Getting A Testosterone Shot Make You Lose Sleep

Source: https://academic.oup.com/jcem/article/88/8/3605/2845283#:~:text=Short%2Dterm%20administration%20of%20high,%2C%20mental%2C%20or%20metabolic%20function.